WHO ICTRP trial
Investigating the in vivo bioequivalence of Ibrutinib 140 mg capsule
IRCT20210519051345N71 · Iranian Registry of Clinical Trials (IRCT) · Not Recruiting
Key facts
| Trial ID | IRCT20210519051345N71 |
|---|---|
| Public title | Investigating the in vivo bioequivalence of Ibrutinib 140 mg capsule |
| Scientific title | In vivo fasted-state bioequivalence study of Ibrutinib 140 mg Capsules manufactured by Sobhan oncology Pharmaceutical Co. compared to innovator product |
| Primary sponsor | Tabriz University of Medical Sciences |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Phase | Bioequivalence |
| Countries | Iran (Islamic Republic of) |
| Conditions | In the present study, the products will be administered to healthy volunteers. |
| Interventions | Intervention 1: Intervention group: Intervention group will receive a single oral dose of test product (Ibrutinib capsule manufactured by Sobhan Oncology Co.) in fasted state. Blood samples will be collected for 24 hours at the mentioned… |
| Registration date | Dec 24, 2024 |
| Target size | 24 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: